[A21-134] Bosutinib (chronic myelogenous leukaemia) - Addendum to Commission A21-79
Last updated 19.11.2021
Project no.:
A21-134
Commission:
Commission awarded on 12.10.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Treatment of adult patients with newly-diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML)
Unchanged after addendum:
Hint of lesser benefit
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Accompanying information| Project no. | Title | Status |
|---|---|---|
| A21-79 | Bosutinib (chronic myeloid leukaemia) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021-11-19 A G-BA decision was published.